|
Summary Information: ASLAN Pharmaceuticals Limited American Depositary Shares NASDAQ:ASLN |
  [email protected] |
Our Main Pages Stocks.TRoach.Net TRoach.Org TRoach.Net |
_Description: ASLAN Pharmaceuticals, a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of Kathleen M. Metters, PhD, as an independent director. Dr Metters has more than 30 years’ experience in the discovery and development of novel therapies for the treatment of chronic diseases, including autoimmune diseases. Dr Metters is a member of several boards, including Hemoshear Therapeutics LLC and Pharmaxis Ltd (ASX:PSX). Most recently, she was Chief Executive Officer and President of Lycera Corp, where she spearheaded a robust pipeline of proprietary and partnered immune modulator programs.
__The following are links to various summary and news pages for __ASLAN Pharmaceuticals Limited American Depositary Shares [ ASLN ]. __Note: Some Links might not have information for the company. |
|